BioPharmSignal logoBioPharmSignal

Biotech News

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

Tango Therapeutics (TNGX)Tango TherapeuticsFinancing

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares

Related news

TNGXTango Therapeutics2026-06-08 20:01 EST

Tango Therapeutics Announces Proposed $500 Million Public Offering

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ERASErasca2026-07-14 03:10 EST

Erasca Announces Pricing of Upsized Public Offering of Common Stock

ERASErasca2026-07-15 20:01 EST

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

LEGNLegend Biotech Corporation2026-06-18 01:21 EST

Legend Biotech Corporation Announces Pricing of Public Offering

IDYAIDEAYA Biosciences2026-06-10 20:05 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

TNGXTango Therapeutics2026-08-06 22:24 EST

Tango Therapeutics Announces Executive Chair Transition

SNDXSyndax Pharmaceuticals2026-06-04 11:00 EST

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

LEGNLegend Biotech Corporation2026-06-17 20:29 EST

Legend Biotech Corporation Announces Proposed Public Offering

View all latest news

Tango Therapeutics

Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor suppressor loss. Vopimetostat Vopimetostat is a brain-penetrant MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen...

Recent company news

TNGXTango Therapeutics2026-08-06 22:24 EST

Tango Therapeutics Announces Executive Chair Transition

TNGXTango Therapeutics2026-06-22 20:05 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

TNGXTango Therapeutics2026-06-10 02:50 EST

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

TNGXTango Therapeutics2026-06-08 20:01 EST

Tango Therapeutics Announces Proposed $500 Million Public Offering

TNGXTango Therapeutics2026-06-08 10:59 EST

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Stock data

Close
29.00 USD
Market cap
3.11B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States